Quantification of lamivudine-resistant hepatitis B virus mutants by type-specific TaqMan minor groove binder probe assay in patients with chronic hepatitis B

Annals of Clinical Biochemistry

Volumn 45, Issue 1, 2008, Pages 59-64

  Yoshida, Shigeru ^a   Hige, Shuhei ^c   Yoshida, Miyuki ^b   Yamashita, Naoki ^b   Fujisawa, Shin Ichi ^b   Sato, Kaori ^b   Kitamura, Tadashiro ^b   Nishimura, Masaharu ^a   Chuma, Makoto ^c   Asaka, Masahiro ^c   Chiba, Hitoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; TAQ POLYMERASE;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; GENE PROBE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; ANTIVIRAL RESISTANCE; BLOOD; DNA PROBE; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HEPATITIS B VIRUS; LAKE VICTORIA MARBURGVIRUS;

BASE SEQUENCE; DNA PROBES; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAQ POLYMERASE;

EID: 41649109292     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2007.006219     Document Type: Article

References (24)

1. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001;21:243-53
2. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002;97:1618-28
3. Gutfreund KS, Williams M, George R, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000;33:469-75
4. Akuta N, Tsubota A, Suzuki F, et al. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis - an open-cohort study. J Hepatol 2003;38:91-7
5. Maynard M, Parvaz P, Durantel S, et al. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol 2005;42:279-81
6. Westland CE, Yang H, Delaney WE, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005;12:67-73
7. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34
8. Barcena Marugan R, Cid Gomez L, Lopez Serrano P. Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. Transplant Proc 2003;35:1841-3
9. Qaqish RB, Mattes KA, Ritchie DJ. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther 2003;25:3084-99
10. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004;64:1-15
11. Allen MI, Deslauriers M, Andrews CW, et al. Lamivudine Clinical Investigation Group. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7
12. Fu L, Liu S-H, Cheng Y-C. Sensitivity of L-(-)2′,3′- dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999;57:1351-9
13. Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatol Res (the official journal of the Japan Society of Hepatology) 2000;17:31-42
14. Yuen M-F, Kato T, Mizokami M, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003;39:850-5
15. Yoshida S, Yamada Y, Fujisawa S, et al. Dilution-PCR method for wide-range quantitation of HBV DNA. Acta Hepatologica Japonica 2002;43:482-6
16. Natsuizaka M, Hige S, Ono Y, et al. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region. J Viral Hepat 2005;12:154-9
17. Jardi R, Buti M, Rodriguez-Frias F, et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 1999;83:181-7
18. Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702-7
19. Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002;37:259-65
20. Kutyavin IV, Afonina IA, Mills A, et al. 3′-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 2000;28:655-61
21. Punia P, Cane P, Teo C-G, Saunders N. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 2004;40:986-92
22. Umeoka F, Iwasaki Y, Matsumura M, et al. Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol 2006;41:693-701
23. Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999;29:939-45
24. Yadav V, Chu CK. Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study. Bioorg Med Chem Lett 2004;14:4313-17